References
- Our World in Data. Cumulative confirmed COVID-19 deaths and cases. [cited 2021 Apr 6]. Available from: https://ourworldindata.org/grapher/cumulative-deaths-and-cases-covid-19?country=~OWID_WRL.
- Buitrago-Garcia D, Egli-Gany D, Counotte MJ, et al. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: a living systematic review and meta-analysis. PLoS Med. 2020;17(9):e1003346. https://doi.org/https://doi.org/10.1371/journal.pmed.1003346
- Gudbjartsson DF, Helgason A, Jonsson H, et al. Spread of SARS-CoV-2 in the Icelandic population. N Engl J Med. 2020;382:2302–2315. [cited 2021 Apr 6]. Available from: http://www.nejm.org/doi/https://doi.org/10.1056/NEJMoa2006100.
- Emery JC, Russell TW, Liu Y, et al. The contribution of asymptomatic SARS-CoV-2 infections to transmission on the Diamond Princess cruise ship. eLife. 2020;9:e58699. https://doi.org/https://doi.org/10.7554/eLife.58699.
- Ioannidis JPA. Infection fatality rate of COVID-19 inferred from seroprevalence data. Bull World Health Organ. 2021;99:19–33F. [cited 2021 Apr 6]. Available from: http://www.who.int/entity/bulletin/volumes/99/1/20-265892.pdf.
- Hsu LY, Chia PY, Vasoo S. A midpoint perspective on the COVID-19 pandemic. Singapore Med J. 2020;61:381–383. [cited 2021 Apr 6]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7926611/.
- Cromer D, Juno JA, Khoury D, et al. Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection. Nat Rev Immunol. 2021;21:395–404. [cited 2021 Sept 10]. Available from: http://www.nature.com/articles/s41577-021-00550-x.
- Breton G, Mendoza P, Hägglöf T, et al. Persistent cellular immunity to SARS-CoV-2 infection. J Exp Med. 2021;218(4):e20202515. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7845919/.
- Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021;371(6529):eabf4063. Available from: https://science.sciencemag.org/content/371/6529/eabf4063.
- Bonifacius A, Tischer-Zimmermann S, Dragon AC, et al. COVID-19 immune signatures reveal stable antiviral T cell function despite declining humoral responses. Immunity. 2021;54:340–354.e6.
- Sherina N, Piralla A, Du L, et al. Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6-8 months after the infection. Med (NY). 2021;2:281–295.e4.
- Turner JS, Kim W, Kalaidina E, et al. SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans. Nature. 2021;595(7867):421–425. Available from: https://www.nature.com/articles/s41586-021-03647-4.
- Le Bert N, Tan AT, Kunasegaran K, et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020;584:457–462. [cited 2021 Apr 6]. Available from: https://www.nature.com/articles/s41586-020-2550-z.
- Vitale J, Mumoli N, Clerici P, et al. Assessment of SARS-CoV-2 reinfection 1 year after primary infection in a population in Lombardy, Italy. JAMA Intern Med. 2021;181(10):1407–1408. Available from: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2780557.
- Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205–1211. Available from: http://www.nature.com/articles/s41591-021-01377-8.
- Chia WN, Zhu F, Ong SWX, et al. Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study. Lancet Microbe. 2021;2(6):e240-e249. Available from: https://linkinghub.elsevier.com/retrieve/pii/S2666524721000252.
- Long Q-X, Tang X-J, Shi Q-L, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020;26:1200–1204. [cited 2021 Apr 6]. Available from: https://www.nature.com/articles/s41591-020-0965-6.
- Le Bert N, Clapham HE, Tan AT, et al. Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection. J Exp Med. 2021; 3;218(5):e20202617. Available from: https://doi.org/https://doi.org/10.1084/jem.20202617.
- Ministry of Health Singapore. COVID-19 situation report. (2020). [cited 2021 Oct 27]. Available from: https://covidsitrep.moh.gov.sg/.
- Gazit S, Shlezinger R, Perez G, et al. Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections. MedRXiV. 2021, Preprint. https://doi.org/https://doi.org/10.1101/2021.08.24.21262415.
- GenScript USA, Inc. cPass SARS-CoV-2 neutralization antibody detection kit. Version 4. New Jersey: Genscript USA, Inc.; 2020. Available from: https://www.fda.gov/media/143583/download.
- Singapore Statutes Online, Government of Singapore. Infectious Diseases Act; 1977. [cited 2021 October 27]. Available from: https://sso.agc.gov.sg/Act/IDA1976.
- Rydyznski Moderbacher C, Ramirez SI, Dan JM, et al. Antigen-Specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell. 2020;183:996–1012.e19.
- Rodda LB, Netland J, Shehata L, et al. Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. Cell. 2021;184:169–183.e17.
- Takahashi T, Ellingson MK, Wong P, et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature. 2020;588:315–320. [cited 2021 June 5]. Available from: https://www.nature.com/articles/s41586-020-2700-3.
- Talla A, Vasaikar SV, Lemos MP, et al. Longitudinal immune dynamics of mild COVID-19 define signatures of recovery and persistence. bioRxiv. 2021, Preprint. https://doi.org/https://doi.org/10.1101/2021.05.26.442666.
- Ladner JT, Henson SN, Boyle AS, et al. Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with endemic human coronaviruses. Cell Rep Med. 2021;2(1):100189. Available from: https://www.sciencedirect.com/science/article/pii/S2666379120302445.
- Tan C-W, Chia W-N, Young BE, et al. Pan-Sarbecovirus neutralizing antibodies in BNT162b2-immunized SARS-CoV-1 survivors. N Engl J Med. 2021;385:1401–1406. Available from: https://www.nejm.org/doi/https://doi.org/10.1056/NEJMoa2108453.
- McMahan K, Yu J, Mercado NB, et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature. 2021;590:630–634.
- Tan AT, Linster M, Tan CW, et al. Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients. Cell Rep. 2021;34(6):108728. [cited 2021 June 5]. Available from: https://linkinghub.elsevier.com/retrieve/pii/S2211124721000413.
- Bange EM, Han NA, Wileyto P, et al. CD8+ t cells contribute to survival in patients with COVID-19 and hematologic cancer. Nat Med. 2021 Jul;27(7):1280–1289. Available from: http://www.nature.com/articles/s41591-021-01386-7.
- Kalimuddin S, Tham CYL, Qui M, et al. Early T cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset. Med. 2021;2:682–688.e4. [cited 2021 June 5]. Available from: https://www.cell.com/med/abstract/S2666-6340(21)00152-5.